Because K-Ras mutation occurs in over 30% of all human cancers (in particular, 90% of pancreatic cancer) [1-5], our peptide would be useful for delivery method for K-Ras mutated cancers. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.